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TB disease progression are elaborate and complicated undertakings,
since the number of incident cases even in high risk study populations
is usually low and the deﬁnition of latent M.tb infection through a
positive TST or IGRA test result is inaccurate. Using a retrospective
case–control study approach embedded in the Amsterdam Cohort Studies
onHIV infection and AIDS (van denHoek et al., 1988), Sloot et al. (in press)
identify a transcriptional signature within Peripheral BloodMononuclear
Cells, which identiﬁesHIV-positive subjectswho are later diagnosedwith
active TB disease. 55 to 250 days prior to TB diagnosis, IL13 transcription
was detected in six out of 14 TB progressors and linked to differential ex-
pression of 50 additional genes, including type I IFN signature genes,
while no subject in the control group expressed IL13. It can be assumed
that this signature is part of an early host immune response to mycobac-
terial replication in vivo. Whether it is a hallmark of deﬁcient immuno-
logical control of the pathogen invariably linked to progressive disease
or rather reﬂective of pathogen activity independent of subsequent dis-
ease progression remains unclear.
The study by Sloot et al. supports the concept that a diagnostic ap-
proach based on host biomarkers cannot only improve the diagnosis
of active TB in populationswhere a conventional sputum-based diagno-
sis is difﬁcult (e.g. in children, HIV-positives, extra-pulmonary TB), but
might further allow identiﬁcation of subjects with sub-clinically active
M.tb replication. Other recent articles also highlighted the potential of
host biomarkers based on transcriptional (Anderson et al., 2014;
Joosten et al., 2012) or novel T cell signatures (Portevin et al., 2014;
Harari et al., 2011; Schuetz et al., 2011) to improve diagnosis of active
TB and possibly also allow early detection of TB disease progression. It
is widely accepted that often a substantial time interval exists between
infection with M.tb, and diagnosis of symptomatic disease. Individuals
who develop active TB disease after primary infection frequently do so
within the ﬁrst two years (Marais et al., 2004). This speciﬁc characteris-
tic of M.tb infection provides a window of opportunity for more accu-
rate identiﬁcation of individuals currently progressing to active TB
using such novel biomarkers and to target them for early therapeutic in-
tervention. Particularly in high risk populations such as HIV-positives,
TB-contacts or IFN-gamma release assay converters (or TST skin-testDOI of original article: http://dx.doi.org/10.1016/j.ebiom.2014.12.001.
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preventive treatment, which likely result in overtreatment (American
Thoracic Society, 2000). The use of novel host biomarkers in such a
strategy would not only help to signiﬁcantly reduce TB disease morbid-
ity by detection of those subjects with the highest risk of active TB de-
velopment in a “pre-clinical” stadium and motivating them and the
treating medical staff to adhere to preventive treatment, but could
also help to abrogate the MTB transmission chain and hence contribute
to the EndTB Strategy byWHO and to the vision of a world free of TB in
2050 (WHO, 2014).
Future research in the ﬁeld of host biomarkers predictive of TB disease
should be aiming at simplifying current diagnostic approaches into
affordable products applicable on a large scale. Simultaneously, pro-
spective large scale studies on early detection of progressive TB disease
will be necessary (even though complicated to conduct) to further
conﬁrm the diagnostic accuracy and feasibility of these novel bio-
markers in the ﬁeld. Especially, the speciﬁcity for progressive versus
non-progressive/latent M.tb infection needs to be assessed, as well as
the biomarkers ability to distinguish between TB and other inﬂammato-
ry diseases. An assessment of host biomarkers would require validation
work in patient populations with different genetic backgrounds, as eth-
nicity can inﬂuence the composition of the host response, making such
studies even larger. Signiﬁcant effort is still required until the applica-
tion of such novel diagnostic strategies on a large scale could be
achieved. Nonetheless, new diagnostic hostmarkers for early identiﬁca-
tion of progressive TB disease might herald a new era in TB diagnosis
and early treatment.
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